AIDX (20/20 Biolabs) EPS (Basic): $-0.41 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AIDX 20/20 Biolabs Inc AIDX
6 GF Score
Price $0.43
! 1 Warning Sign
View Full Analysis

What is 20/20 Biolabs EPS (Basic)?

20/20 Biolabs AIDX -0.23% 6 EPS (Basic) is $-0.41 as of Mar. 2026. GuruFocus rates AIDX with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

20/20 Biolabs's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.28. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.41.

20/20 Biolabs's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.28. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.41.

20/20 Biolabs's EPS without NRI for the three months ended in Mar. 2026 was $-0.26. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.39.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

20/20 Biolabs  (NAS:AIDX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

20/20 Biolabs EPS (Basic) Related Terms

20/20 Biolabs EPS (Basic) Historical Data

* Premium members only.

The historical data trend for 20/20 Biolabs's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

20/20 Biolabs EPS (Basic) Chart

20/20 Biolabs Annual Data
Trend Dec23 Dec24 Dec25
EPS (Basic)
-0.62 -0.54 -0.36

20/20 Biolabs Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial -0.12 -0.07 0.00 -0.13 -0.28
AIDX
6GF Score
20/20 Biolabs Inc AIDX
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

20/20 Biolabs EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

20/20 Biolabs's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.739-0)/10.347
=-0.36

20/20 Biolabs's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2.175--0.054)/7.657
=-0.28

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.41 mean?
20/20 Biolabs (AIDX) has a EPS (Basic) of $-0.41 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on 20/20 Biolabs and its competitors.
Is 20/20 Biolabs' EPS (Basic) too high?
20/20 Biolabs' current EPS (Basic) is $-0.41. Overall, 20/20 Biolabs has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does 20/20 Biolabs' EPS (Basic) compare to STME and TRIB?
20/20 Biolabs' EPS (Basic) of $-0.41 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on 20/20 Biolabs and its competitors. 20/20 Biolabs's current EPS (Basic) is $-0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 20/20 Biolabs stock overvalued right now?
20/20 Biolabs (AIDX) has a current EPS (Basic) of $-0.41. The current EPS (Basic) is $-0.41. 20/20 Biolabs' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For 20/20 Biolabs (AIDX), the current EPS (Basic) is $-0.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

20/20 Biolabs Business Description

Address 15810 Gaither Road, Suite 235, Gaithersburg, MD, USA, 20877
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
6GF Score

Get the complete analysis for AIDX

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.43
Price